Rasagiline (Anqilai) original manufacturer information and drug source description

Rasagiline (Rasagiline) is a selective monoamine oxidaseB (MAO-B) inhibitor. It is mainly used to treat Parkinson's disease. It can delay the degradation of dopamine, thereby improving motor symptoms. The original manufacturer of the drug is Teva Pharmaceutical Industries Ltd. (Teva Pharmaceuticals), a Swiss pharmaceutical company. The original drug is marketed in many countries and regions under the brand name Azilect. Teva Pharmaceuticals has a complete drug R&D, production and quality management system around the world to ensure that drugs comply with international standards during production, circulation and storage.

In terms of drug sources, rasagiline original drugs are mainly supplied to hospitals, pharmacies and medical institutions in various countries through formal channels. In China, patients can purchase imported and registered original drugs through large tertiary hospitals or specific pharmacies. Due to the strict production and quality standards of the original drug, its stable efficacy, reliable safety and tolerability, it is widely recommended in clinical practice for the treatment of early and mid-stage Parkinson's disease.

In recent years, some domestic generic drug manufacturers have also developed rasagiline. However, compared with the original drug, its clinical use time is shorter, and its long-term efficacy and safety need further verification. Therefore, when purchasing drugs, patients and doctors should give priority to formal channels and manufacturers approved by the national drug regulatory department to ensure drug quality and therapeutic effects. For generic drugs, attention should be paid to verifying the manufacturer’s qualifications, approval number, and drug insert information to avoid using drugs from unknown sources.

Generally speaking, the original manufacturer of rasagiline is Teva Pharmaceuticals, and the drugs are mainly supplied through formal channels, ensuring the quality and efficacy of the drugs. Clinically, patients can rationally choose original drugs or verified generic drugs under the guidance of doctors and purchase them through legal channels, which can ensure the safety and stability of treatment to the greatest extent, while effectively improving the symptoms of Parkinson's disease and improving the quality of life.

Reference materials:https://www.drugs.com/